Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Acinetobacter baumannii, a Gram-negative, nosocomial, opportunistic pathogen is commonly infectious in immunocompromised patients. More specifically patients develop healthcare-associated infections (HAI) spanning beyond sepsis, pneumonia, meningitis, and urinary tract infections. Due to its rapid ability to acquire antibiotic resistance, it has raised the necessity to discern a novel therapeutic treatment that can be effectively used against the multidrug resistant (MDR) A. baumannii. Cooper University Hospital (CUH) faced an increased case load of patients that were infected with MDR A. baumannii. The patient isolates obtained from CUH were highly resistant to the 22 standard-of-care antibiotics. With the recent introduction of novel antibiotics released onto the market, the possibility of antimicrobial synergism between old and new drugs was tested. We tested to see if drug synergy existed between levofloxacin and cefepime, and levofloxacin and amikacin. We also studied the potency and potential synergism of the newer drug cefiderocol in combination with the 22 standard-of-care antibiotics. Levofloxacin and amikacin showed limited efficacy as a drug combination making it an ineffective option in a clinical setting. However, levofloxacin and cefepime showed promise as an effective therapeutic combination. Experimental studies with cefiderocol showed contamination, requiring future evaluation with cefiderocol. We plan to further explore the drug combination levofloxacin and cefepime against other patient isolates in the collection. Obtaining useful dual antibiotic therapies can provide clinicians with an immediate resource to help treat patients with highly drug-resistant A. baumannii infections.
Keywords
Acinetobacter baumannii, Acinetobacter Infections, Antibiotic Resistance, Antimicrobial Synergism, Antimicrobial Drug Resistance, Antibiotic Therapies
Disciplines
Bacteria | Bacterial Infections and Mycoses | Infectious Disease | Investigative Techniques | Medicine and Health Sciences | Pharmaceutical Preparations | Therapeutics
Document Type
Poster
Included in
Bacteria Commons, Bacterial Infections and Mycoses Commons, Infectious Disease Commons, Investigative Techniques Commons, Pharmaceutical Preparations Commons, Therapeutics Commons
Evaluation of the Efficacy of Novel Drugs and Combinations Against Extensively- and Pan-Drug Resistant Acinetobacter baumannii Isolates
Acinetobacter baumannii, a Gram-negative, nosocomial, opportunistic pathogen is commonly infectious in immunocompromised patients. More specifically patients develop healthcare-associated infections (HAI) spanning beyond sepsis, pneumonia, meningitis, and urinary tract infections. Due to its rapid ability to acquire antibiotic resistance, it has raised the necessity to discern a novel therapeutic treatment that can be effectively used against the multidrug resistant (MDR) A. baumannii. Cooper University Hospital (CUH) faced an increased case load of patients that were infected with MDR A. baumannii. The patient isolates obtained from CUH were highly resistant to the 22 standard-of-care antibiotics. With the recent introduction of novel antibiotics released onto the market, the possibility of antimicrobial synergism between old and new drugs was tested. We tested to see if drug synergy existed between levofloxacin and cefepime, and levofloxacin and amikacin. We also studied the potency and potential synergism of the newer drug cefiderocol in combination with the 22 standard-of-care antibiotics. Levofloxacin and amikacin showed limited efficacy as a drug combination making it an ineffective option in a clinical setting. However, levofloxacin and cefepime showed promise as an effective therapeutic combination. Experimental studies with cefiderocol showed contamination, requiring future evaluation with cefiderocol. We plan to further explore the drug combination levofloxacin and cefepime against other patient isolates in the collection. Obtaining useful dual antibiotic therapies can provide clinicians with an immediate resource to help treat patients with highly drug-resistant A. baumannii infections.